After hepatitis resolved, a different immunotherapy or targeted therapy was started in 9 patients with PD-1 inhibitor-induced hepatitis and 12 patients with ipilimumab- induced hepatitis. This evidence concerns the gene PDCD1 and hepatitis A virus infection.